- Issuer ticker
-
BCAX
- Reported as of
-
12 Sep 2024
- Net transaction value
-
$0
Source evidence
Original filing metadata and source links for verification.
5 source fields
- SEC form
-
3
- Accepted by SEC
-
12 Sep 2024, 21:00:11 UTC
Reporting owner
1 detail
- Reporting owner signature
-
/s/ Lara Meisner, Attorney-in-Fact
Key filing fact
Kate Haviland filed Form 3 for Bicara Therapeutics Inc. (BCAX) on 12 Sep 2024.
Key facts
- This page summarizes Kate Haviland's Form 3 filing for Bicara Therapeutics Inc. (BCAX).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Sep 2024, 21:00.
Change
- Previous filing in this sequence was filed on 18 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
Ownership activity is grounded in SEC Form 3 disclosures.
View source filing
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCAX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
-
- Shares after
- 7,437
- Date
- 12 Sep 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BCAX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
-
- Shares after
- Date
- 12 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 52,063
- Exercise price
- $3.79
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote
SEC remarks
Exhibit 24 - Power of Attorney